Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2005 2
2006 4
2007 4
2008 9
2009 12
2010 11
2011 14
2012 19
2013 11
2014 8
2015 8
2016 11
2017 17
2018 21
2019 11
2020 14
2021 13
2022 8
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
Tien JC, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, Yang J, Mannan R, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Lord CJ, Ding K, Chinnaiyan AM. Tien JC, et al. Among authors: lord cj. bioRxiv [Preprint]. 2024 Mar 21:2024.03.20.585990. doi: 10.1101/2024.03.20.585990. bioRxiv. 2024. PMID: 38562774 Free PMC article. Preprint.
Complex synthetic lethality in cancer.
Ryan CJ, Devakumar LPS, Pettitt SJ, Lord CJ. Ryan CJ, et al. Among authors: lord cj. Nat Genet. 2023 Dec;55(12):2039-2048. doi: 10.1038/s41588-023-01557-x. Epub 2023 Nov 30. Nat Genet. 2023. PMID: 38036785 Review.
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Baxter JS, Brough R, Krastev DB, Song F, Sridhar S, Gulati A, Alexander J, Roumeliotis TI, Kozik Z, Choudhary JS, Haider S, Pettitt SJ, Tutt ANJ, Lord CJ. Baxter JS, et al. Among authors: lord cj. Mol Oncol. 2024 Feb;18(2):369-385. doi: 10.1002/1878-0261.13537. Epub 2023 Oct 22. Mol Oncol. 2024. PMID: 37866880 Free PMC article.
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
Bland P, Saville H, Wai PT, Curnow L, Muirhead G, Nieminuszczy J, Ravindran N, John MB, Hedayat S, Barker HE, Wright J, Yu L, Mavrommati I, Read A, Peck B, Allen M, Gazinska P, Pemberton HN, Gulati A, Nash S, Noor F, Guppy N, Roxanis I, Pratt G, Oldreive C, Stankovic T, Barlow S, Kalirai H, Coupland SE, Broderick R, Alsafadi S, Houy A, Stern MH, Pettit S, Choudhary JS, Haider S, Niedzwiedz W, Lord CJ, Natrajan R. Bland P, et al. Among authors: lord cj. Nat Genet. 2023 Aug;55(8):1311-1323. doi: 10.1038/s41588-023-01460-5. Epub 2023 Jul 31. Nat Genet. 2023. PMID: 37524790 Free PMC article.
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Pettitt SJ, Shao N, Zatreanu D, Frankum J, Bajrami I, Brough R, Krastev DB, Roumeliotis TI, Choudhary JS, Lorenz S, Rust A, de Bono JS, Yap TA, Tutt ANJ, Lord CJ. Pettitt SJ, et al. Among authors: lord cj. Oncogene. 2023 Sep;42(36):2701-2709. doi: 10.1038/s41388-023-02782-8. Epub 2023 Jul 25. Oncogene. 2023. PMID: 37491606 Free PMC article.
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, Alexander J, Baxter JS, Brough R, Gulati A, Haider S, Raghunandan M, Song F, Sridhar S, Forment JV, O'Connor MJ, Davies BR, van Vugt MATM, Krastev DB, Pettitt SJ, Tutt ANJ, Rottenberg S, Lord CJ. Zelceski A, et al. Among authors: lord cj. Cell Rep. 2023 May 30;42(5):112484. doi: 10.1016/j.celrep.2023.112484. Epub 2023 May 9. Cell Rep. 2023. PMID: 37163373 Free article.
Systemic Therapy for Hereditary Breast Cancers.
Harvey-Jones EJ, Lord CJ, Tutt ANJ. Harvey-Jones EJ, et al. Among authors: lord cj. Hematol Oncol Clin North Am. 2023 Feb;37(1):203-224. doi: 10.1016/j.hoc.2022.08.018. Hematol Oncol Clin North Am. 2023. PMID: 36435611 Free article. Review.
196 results